MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
But biomarker enrichment and toxicity remain key for FX-909.
